licoisoflavone A

from Sophra mooracroftiana; structure in first source

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Acute Lung Injury 01/01/2019 - "All these disclosed the detoxification and antioxidation effects of licorice on acute lung injury induced by PQ, and glycyrol, isolicoflavonol, licochalcone A, 18beta-glycyrrhetinic acid, and licoisoflavone A upregulated CYP450 and Nrf2 pathways underlying the alexipharmic mechanisms of licorice."
2.	Hypertrophy 03/01/2020 - "High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3."
3.	Cardiomegaly (Heart Hypertrophy) 03/01/2020 - "Combining high content screening and liquid chromatography mass spectrometry, four compounds with anti-cardiac hypertrophy effects were identified from TMYX, which includes emodin, licoisoflavone A, licoricone and glyasperin A. " 03/01/2020 - "These results suggested that licoisoflavone A is a potential Sirt3 activator with therapeutic effect on cardiac hypertrophy."
4.	COVID-19 01/01/2023 - "Among the 60 compounds, six compounds (magnolol, glycyrrhisoflavone, licoisoflavone A, emodin, echinatin, and quercetin) were identified showing a dose-dependent inhibition effect on the SARS-CoV-2 infection, including two inhibitors (echinatin and quercetin) of the main protease (Mpro), as well as two inhibitors (glycyrrhisoflavone and licoisoflavone A) of the RNA-dependent RNA polymerase (RdRp). "

1.	Emodin (Archin)
2.	Sirtuin 3
3.	Therapeutic Uses
4.	RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)
5.	Quercetin
6.	Peptide Hydrolases (Proteases)
7.	glycyrol
8.	18alpha-glycyrrhetinic acid
9.	licochalcone A
10.	magnolol